{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:36:11Z","timestamp":1782408971865,"version":"3.54.5"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>\n                      Starting in March 2021, the Organ Procurement and Transplantation Network (OPTN) mandated testing and reporting of hepatitis C virus (HCV), hepatitis B virus, and HIV at 4\u20138\u2009wk posttransplantation. The aim of this study was to assess the rates of detectable HCV viremia in HCV nucleic acid test (NAT) negative recipients of liver allografts from HCV antibody-positive\/NAT-negative (Ab\n                      <jats:sup>+<\/jats:sup>\n                      \/NAT\n                      <jats:sup>\u2013<\/jats:sup>\n                      ) donors in a nationwide cohort after the institution of the reporting mandate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>\n                      Post\u2013liver transplant (LT) HCV viremia and patient\/graft outcomes were compared between 2 groups using the OPTN database: HCV negative LT recipients of donors with HCV Ab\n                      <jats:sup>+<\/jats:sup>\n                      \/NAT\n                      <jats:sup>\u2013<\/jats:sup>\n                      and HCV Ab\n                      <jats:sup>\u2013<\/jats:sup>\n                      \/NAT\n                      <jats:sup>\u2013<\/jats:sup>\n                      between March 2021 and March 2023.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      Among 7447 recipients (Ab\n                      <jats:sup>+<\/jats:sup>\n                      \/NAT\n                      <jats:sup>\u2013<\/jats:sup>\n                      N\u2005=\u2005380 and Ab\n                      <jats:sup>\u2013<\/jats:sup>\n                      \/NAT\n                      <jats:sup>\u2013<\/jats:sup>\n                      N\u2005=\u20057067), 5 (1.5%) of Ab\n                      <jats:sup>+<\/jats:sup>\n                      \/NAT\n                      <jats:sup>\u2013<\/jats:sup>\n                      LT recipients and 5 (0.09%) of Ab\n                      <jats:sup>\u2013<\/jats:sup>\n                      \/NAT\n                      <jats:sup>\u2013<\/jats:sup>\n                      LT recipients reported a positive HCV NAT result during the median follow-up period of 182 (175\u2013199) d post-LT. In this early period of mandated reporting, HCV NAT results at 6 mo posttransplant were available for 85.3% of the Ab\n                      <jats:sup>+<\/jats:sup>\n                      \/NAT\n                      <jats:sup>\u2013<\/jats:sup>\n                      group and 77.1% of the Ab\n                      <jats:sup>\u2013<\/jats:sup>\n                      \/NAT\n                      <jats:sup>\u2013<\/jats:sup>\n                      group. Overall and graft survival were comparable among the 2 groups at 6 and 12 mo post-LT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>\n                      After the OPTN mandate of HCV testing post-LT starting March 2021, the rate of positive HCV NAT results was 1.5% in HCV NAT\n                      <jats:sup>\u2013<\/jats:sup>\n                      recipients of liver allografts from HCV Ab\n                      <jats:sup>+<\/jats:sup>\n                      \/NAT\n                      <jats:sup>\u2013<\/jats:sup>\n                      donors. Improved compliance with the mandated testing can help in the early detection of HCV transmission among LT recipients in this cohort and may help prevent associated post-LT complications.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005497","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T04:00:55Z","timestamp":1753329655000},"page":"1871-1876","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Risk of Hepatitis C Transmission After Liver Transplantation From Hepatitis C Nonviremic, Antibody-positive Donors Into Nonviremic Recipients in the Era of Mandated Testing"],"prefix":"10.1097","volume":"109","author":[{"given":"Kenji","family":"Okumura","sequence":"first","affiliation":[{"name":"Department of Surgery, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Misawa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Surgery, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Dhand","sequence":"additional","affiliation":[{"name":"Department of Surgery, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"R1-20251126","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/003335491312800403","article-title":"PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation.","volume":"128","author":"Seem","year":"2013","journal-title":"Public Health Rep"},{"key":"R2-20251126","doi-asserted-by":"crossref","first-page":"61","DOI":"10.15585\/mmwr.mm6803a2","article-title":"Characteristics of deceased solid organ donors and screening results for hepatitis B, C, and human immunodeficiency viruses\u2014United States, 2010\u20132017.","volume":"68","author":"Abara","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R3-20251126","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/TP.0000000000001673","article-title":"The \u201cPHS increased risk\u201d label is associated with nonutilization of hundreds of organs per year.","volume":"101","author":"Volk","year":"2017","journal-title":"Transplantation"},{"key":"R4-20251126","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1111\/ajt.15352","article-title":"Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014\u20132017.","volume":"19","author":"Bixler","year":"2019","journal-title":"Am J Transplant"},{"key":"R5-20251126","doi-asserted-by":"crossref","first-page":"702","DOI":"10.7326\/M17-2451","article-title":"The drug overdose epidemic and deceased-donor transplantation in the United States: a national registry study.","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"key":"R6-20251126","doi-asserted-by":"crossref","first-page":"101986","DOI":"10.5500\/wjt.v15.i2.101986","article-title":"Rise in deaths from drug overdose and firearm injury during coronavirus disease 2019 pandemic and its impact on organ transplantation.","volume":"15","author":"Dhand","year":"2025","journal-title":"World J Transplant"},{"key":"R7-20251126","article-title":"Treatment of HCV-uninfected transplant recipients receiving organs from HCV-viremic donors."},{"key":"R8-20251126","doi-asserted-by":"crossref","first-page":"ciad319","DOI":"10.1093\/cid\/ciad319","article-title":"hepatitis C guidance 2023 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection.","author":"Bhattacharya","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R9-20251126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6904a1","article-title":"Assessing solid organ donors and monitoring transplant recipients for human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection\u2014U.S. Public Health Service Guideline, 2020.","volume":"69","author":"Jones","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"R10-20251126","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/TP.0000000000005174","article-title":"Outcomes of liver transplantation from hepatitis C virus-positive DCD donors and its utilization among centers in the United States.","volume":"109","author":"Punjala","year":"2025","journal-title":"Transplantation"},{"key":"R11-20251126","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/hep.29704","article-title":"Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients.","volume":"67","author":"Bari","year":"2018","journal-title":"Hepatology"},{"key":"R12-20251126","doi-asserted-by":"crossref","first-page":"100318","DOI":"10.1016\/j.aohep.2021.100318","article-title":"Outcomes of hepatitis C virus seropositive donors to hepatitis C virus seronegative liver recipients: a large single center analysis.","volume":"24","author":"Sobotka","year":"2021","journal-title":"Ann Hepatol"},{"key":"R13-20251126","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1111\/ajt.15393","article-title":"Quantifying the risk of undetected HIV, hepatitis B virus, or hepatitis C virus infection in Public Health Service increased risk donors.","volume":"19","author":"Jones","year":"2019","journal-title":"Am J Transplant"},{"key":"R14-20251126","article-title":"Understanding the risk of transmission of HIV, hepatitis B, and hepatitis C from U.S. PHS increased risk donors."},{"key":"R15-20251126","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.idc.2023.05.002","article-title":"Minimizing the risk of donor-derived events and maximizing organ utilization through education and policy development.","volume":"37","author":"La Hoz","year":"2023","journal-title":"Infect Dis Clin North Am"},{"key":"R16-20251126","article-title":"Unexpected HCV donor-derived transmissions on the rise."},{"issue":"Suppl. 1","key":"R17-20251126","doi-asserted-by":"crossref","first-page":"e14305","DOI":"10.1111\/tid.14305","article-title":"Hepatitis B transmission\/reactivation associated with hepatitis B core antibody and hepatitis C nucleic acid testing positive organs: a report from the Organ Procurement and Transplantation Network Disease Transmission Advisory Committee.","volume":"26","author":"Te","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"R18-20251126","article-title":"Hepatitis C diagnostic testing\u2013core concepts."},{"key":"R19-20251126","doi-asserted-by":"crossref","first-page":"E737","DOI":"10.9778\/cmajo.20160084","article-title":"Systematic review of the accuracy of antibody tests used to screen asymptomatic adults for hepatitis C infection.","volume":"4","author":"Cadieux","year":"2016","journal-title":"CMAJ Open"},{"key":"R20-20251126","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R21-20251126","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/TP.0000000000004929","article-title":"Organ nonutilization following revision to the public health service donor risk criteria for HIV, HCV, or HBV transmission.","volume":"108","author":"Patel","year":"2024","journal-title":"Transplantation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:00:21Z","timestamp":1764169221000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005497","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]}}}